Live from the NIH registry
Studies recruiting near Norwich right now
Top 25 of 127 recruiting studies, sorted by proximity — each links to its official registry page
Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions
Obesity
N/A
Interventional 378 participants sought
University of Connecticut — Storrs, Connecticut (19.7 mi)
· Sponsor: University of Connecticut
A Novel Program Using Ride-on Toys to Improve Upper Extremity Function in Children With Hemiplegia
Hemiplegia, Cerebral Palsy
N/A
Interventional 30 participants sought
Physical Therapy Program, Department of Kinesiology, University of Connecticut — Storrs, Connecticut (19.7 mi)
· Sponsor: University of Connecticut
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Phase 3
Interventional 400 participants sought
Smilow Cancer Hospital - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: Pfizer
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma
Phase 3
Interventional 562 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: SWOG Cancer Research Network
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Refractory Differentiated Thyroid Gland Carcinoma
Phase 3
Interventional 264 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma
Phase 3
Interventional 1,273 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: SWOG Cancer Research Network
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3
Interventional 630 participants sought
Eastern Connecticut Hematology and Oncology — Norwich, Connecticut (1.9 mi)
· Sponsor: BeOne Medicines
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8
Phase 2
Interventional 108 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: National Cancer Institute (NCI)
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Phase 3
Interventional 382 participants sought
Hartford HealthCare - Manchester — Manchester, Connecticut (27.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3
Interventional 1,200 participants sought
Eastern CT Hematology & Oncology Associates ( Site 0033) — Norwich, Connecticut (1.9 mi)
· Sponsor: Merck Sharp & Dohme LLC
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: SWOG Cancer Research Network
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Resectable Intrahepatic Cholangiocarcinoma
Phase 2
Interventional 27 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: National Cancer Institute (NCI)
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Cancer
N/A
Observational 500 participants sought
Eastern CT and Hematology and Oncology Associates — Norwich, Connecticut (1.9 mi)
· Sponsor: Tempus AI
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
Macular Edema Secondary to Inflammation
Phase 3
Interventional 600 participants sought
Retina Group of New England, PC — Waterford, Connecticut (14.6 mi)
· Sponsor: Kodiak Sciences Inc
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Lymphoma, Non-Hodgkin, Multiple Myeloma
Phase 2
Interventional 4,200 participants sought
William W. Backus Hospital — Norwich, Connecticut (1.9 mi)
· Sponsor: American Society of Clinical Oncology
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Cervical Cancer
N/A
Interventional 840 participants sought
Hartford Healthcare Medical Group-Manchester — Manchester, Connecticut (27.3 mi)
· Sponsor: GOG Foundation
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Breast Cancer, HER2-positive Breast Cancer
Phase 2
Interventional 500 participants sought
Smilow Cancer Hospital Care center at Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: Dana-Farber Cancer Institute
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Stage I Breast Cancer
Phase 3
Interventional 1,670 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: NRG Oncology
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Radiation Retinopathy, Visual Impairment
Phase 3
Interventional 600 participants sought
Retina Consultants — Manchester, Connecticut (27.3 mi)
· Sponsor: Jaeb Center for Health Research
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration, nAMD
Phase 3
Interventional 304 participants sought
Retina Group of New England — Waterford, Connecticut (14.6 mi)
· Sponsor: Amgen
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 626 participants sought
Eastern Connecticut Hematology and Oncology Associates — Norwich, Connecticut (1.9 mi)
· Sponsor: Mirati Therapeutics Inc.
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Phase 2
Interventional 360 participants sought
Seaport Investigator Site — Cromwell, Connecticut (29.0 mi)
· Sponsor: Seaport Therapeutics
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: National Cancer Institute (NCI)
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Metastatic Breast Cancer
Phase 3
Interventional 500 participants sought
Smilow Cancer Hospital - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: American Society of Clinical Oncology